244 related articles for article (PubMed ID: 21818112)
1. Dynamics of the emergence of dasatinib and nilotinib resistance in imatinib-resistant CML patients.
Gruber FX; Ernst T; Porkka K; Engh RA; Mikkola I; Maier J; Lange T; Hochhaus A
Leukemia; 2012 Jan; 26(1):172-7. PubMed ID: 21818112
[No Abstract] [Full Text] [Related]
2. Use of dasatinib and nilotinib in imatinib-resistant chronic myeloid leukemia: translating preclinical findings to clinical practice.
DeAngelo DJ; Attar EC
Leuk Lymphoma; 2010 Mar; 51(3):363-75. PubMed ID: 20038231
[TBL] [Abstract][Full Text] [Related]
3. [Treatment of imatinib-intolerant or -resistant CML patients].
Kimura S
Nihon Rinsho; 2012 Apr; 70 Suppl 2():304-8. PubMed ID: 23133972
[No Abstract] [Full Text] [Related]
4. Dasatinib treatment can overcome imatinib and nilotinib resistance in CML patient carrying F359I mutation of BCR-ABL oncogene.
Barańska M; Lewandowski K; Gniot M; Iwoła M; Lewandowska M; Komarnicki M
J Appl Genet; 2008; 49(2):201-3. PubMed ID: 18436994
[TBL] [Abstract][Full Text] [Related]
5. Two new agents effective in Gleevec-resistant CML.
Cancer Biol Ther; 2004 Dec; 3(12):1198-9. PubMed ID: 15864854
[No Abstract] [Full Text] [Related]
6. Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants.
Redaelli S; Piazza R; Rostagno R; Magistroni V; Perini P; Marega M; Gambacorti-Passerini C; Boschelli F
J Clin Oncol; 2009 Jan; 27(3):469-71. PubMed ID: 19075254
[No Abstract] [Full Text] [Related]
7. Looking beyond imatinib: next line of targeted drugs for CML shows promise.
Hampton T
JAMA; 2006 Jan; 295(4):369-70. PubMed ID: 16434621
[No Abstract] [Full Text] [Related]
8. Strategies for overcoming imatinib resistance in chronic myeloid leukemia.
Kujawski L; Talpaz M
Leuk Lymphoma; 2007 Dec; 48(12):2310-22. PubMed ID: 18067005
[TBL] [Abstract][Full Text] [Related]
9. Improving frontline treatment for chronic myeloid leukemia: emerging evidence for use of nilotinib and dasatinib.
Erba HP; Pham DC; Zaiden R; Vu H; Tai S
Clin Adv Hematol Oncol; 2011 Oct; 9(10):734-45. PubMed ID: 22252576
[TBL] [Abstract][Full Text] [Related]
10. Hematology: Nilotinib and dasatinib--new 'magic bullets' for CML?
Breccia M
Nat Rev Clin Oncol; 2010 Oct; 7(10):557-8. PubMed ID: 20877419
[No Abstract] [Full Text] [Related]
11. Dasatinib and nilotinib in imatinib-resistant Philadelphia-positive chronic myelogenous leukemia: a 'head-to-head comparison'.
Rosti G; Castagnetti F; Gugliotta G; Palandri F; Martinelli G; Baccarani M
Leuk Lymphoma; 2010 Apr; 51(4):583-91. PubMed ID: 20302388
[TBL] [Abstract][Full Text] [Related]
12. Dasatinib is effective in imatinib-resistant CML.
Cannell E
Lancet Oncol; 2007 Apr; 8(4):286. PubMed ID: 17431950
[No Abstract] [Full Text] [Related]
13. New strategies in controlling drug resistance.
Frame D
J Manag Care Pharm; 2007 Oct; 13(8 Suppl A):13-7. PubMed ID: 17970610
[TBL] [Abstract][Full Text] [Related]
14. Comparison of imatinib, dasatinib, nilotinib and INNO-406 in imatinib-resistant cell lines.
Deguchi Y; Kimura S; Ashihara E; Niwa T; Hodohara K; Fujiyama Y; Maekawa T
Leuk Res; 2008 Jun; 32(6):980-3. PubMed ID: 18191450
[TBL] [Abstract][Full Text] [Related]
15. Drugs offer new hope for patients with CML who are resistant to imatinib.
Oestreicher P
ONS Connect; 2007 Jul; 22(7):20-1. PubMed ID: 17694781
[No Abstract] [Full Text] [Related]
16. Treatment options for patients with chronic myeloid leukemia who are resistant to or unable to tolerate imatinib.
Stein B; Smith BD
Clin Ther; 2010 May; 32(5):804-20. PubMed ID: 20685492
[TBL] [Abstract][Full Text] [Related]
17. A retrospective analysis of therapy adherence in imatinib resistant or intolerant patients with chronic myeloid leukemia receiving nilotinib or dasatinib in a real-world setting.
Guérin A; Chen L; Wu EQ; Ponce de Leon D; Griffin JD
Curr Med Res Opin; 2012 Jul; 28(7):1155-62. PubMed ID: 22738777
[TBL] [Abstract][Full Text] [Related]
18. [Roles of the 2nd generation TKIs for CML].
Matsumura I
Rinsho Ketsueki; 2011 Oct; 52(10):1610-8. PubMed ID: 21971238
[No Abstract] [Full Text] [Related]
19. Optimizing therapy for patients with chronic myelogenous leukemia in chronic phase.
Kantarjian HM; Cortes J; La Rosée P; Hochhaus A
Cancer; 2010 Mar; 116(6):1419-30. PubMed ID: 20120030
[TBL] [Abstract][Full Text] [Related]
20. Dasatinib, high-dose imatinib and nilotinib for the treatment of imatinib-resistant chronic myeloid leukaemia: a systematic review and economic evaluation.
Loveman E; Cooper K; Bryant J; Colquitt JL; Frampton GK; Clegg A
Health Technol Assess; 2012; 16(23):iii-xiii, 1-137. PubMed ID: 22564553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]